//fpnotebook.com/
Atrophic Vaginitis
Aka: Atrophic Vaginitis, Vaginal Atrophy, Vulvovaginal Atrophy, Genitourinary Syndrome of Menopause
- See Also
- Menopause
- Dyspareunia
- Vaginitis
- Epidemiology
- Prevalence: 50% of post-menopausal women within first 3 years
- Causes
- Menopause (most common)
- Vulvovaginal Atrophy and dryness symptomatic in 50% of postmenopausal women (due to low Estrogen)
- Only 25% of symptomatic women seek medical care
- Antiestrogen medications (e.g. Raloxifene, Tamoxifen, GnRH agonists)
- Breast Feeding women
- Central Amenorrhea
- Pathophysiology
- Related to decreased Estrogen with Menopause
- Vaginal effects
- Vaginal epithelium thins with decreased lubrication
- Vaginal canal narrowing
- Bleeding or pain on intercourse
- Vulvar mucosa thinning
- Vulvar burning or irritation
- Dyspareunia due to introitus narrowing
- Glycogen loss with altered Vaginal pH and flora
- Symptoms
- Vaginal Dryness
- Vaginal or vulvar burning, itching or irritation
- Dyspareunia
- Vaginal Discharge
- Urinary urgency
- Signs
- Vaginal Discharge that is thin or clear
- Vaginal introitus narrowing
- Loss of labia minora
- Vaginal mucosa changes
- Mucosa is thin, pale and dry with reduced elasticity
- Vaginal rugae lost
- Mucosa may be irritated and friable
- Labs
- Vaginal pH 5 to 7
- Complications
- Recurrent Urinary Tract Infections
- Management
- See Menopause
- Symptomatic measures (first-line for mild symptoms)
- Vaginal Moisturizers (Replens) applied three times weekly
- Vaginal Lubricant (e.g. Astroglide) applied before intercourse
- Topical Vaginal Estrogen (second-line for moderate symptoms)
- Does not require systemic Progesterone (in intact Uterus) if used <1 year
- Low dose Topical Estrogen (e.g. Vagifem, Estring, Estrace or Premarin vaginal cream)
- Reduces risk of Recurrent Urinary Tract Infection
- Suckling (2006) Cochrane Database Syst Rev (4): CD001500 [PubMed]
- Intravaginal Prasterone (Intrarosa, synthetic DHEA)
- Vaginal Dehydroepiadrosterone that increases epithelial thickness and decreases Dyspareunia
- Indicated in Dyspareunia and moderate to severe Vulvovaginal Atrophy
- Although marketed as non-Estrogen, it is DHEA which converts to Estrogens and androgens in vaginal tissue
- Expensive (>$200/month)
- Systemic Estrogens (third-line for refractory symptoms)
- Precautions
- Do not use Unopposed Estrogen with intact Uterus (requires concurrent Progesterone)
- Continuous Estrogen Replacement
- Sequential Estrogen Replacement
- Transdermal Estrogen Replacement
- Higher dose Topical Estrogen (e.g. FemRing)
- Requires Progesterone (in intact Uterus), unlike low dose Topical Estrogens
- Other options (refractory symptoms and unable to use Estrogens)
- Osphena (ospemifene)
- Selective Estrogen receptor modifier (SERM) with Vaginal Estrogenic effect (unlike Raloxifene and Tamoxifen)
- FDA-approved for severe Dyspareunia
- Risk of venous thrombosis and Hot Flashes (similar to Raloxifene and Tamoxifen)
- Expensive (> $200/month) with limited indications beyond other measures
- Dose: 60 mg once daily with food
- (2013) Prescr Lett 20(6):33
- Fractional Carbon-Dioxide Laser Therapy
- Results in microabrasions that promote increased Blood Flow and thicken vaginal tissue
- Decreases Dyspareunia
- Similar efficacy to Vaginal Estrogens, but not FDA approved and risk of burns and scarring
- https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic
- Paralso (2020) Menopause 27(1):50-6 [PubMed]
- References
- Hill (2016) Am Fam Physician 94(11): 884-9 [PubMed]
- Hill (2021) Am Fam Physician 103(10):597-604 [PubMed]
- Ringel (2020) Am Fam Physician 102(9):550-7 [PubMed]
- Seehusen (2014) Am Fam Physician 90(7): 465-70 [PubMed]